Metformin
Metformin is an oral small-molecule drug of the biguanide class and the standard first-line pharmacotherapy for type 2 diabetes mellitus.
Metformin is an oral small-molecule drug of the biguanide class and the standard first-line pharmacotherapy for type 2 diabetes mellitus. It lowers blood glucose primarily by suppressing hepatic gluconeogenesis and improving peripheral insulin sensitivity, and because it does not directly stimulate insulin secretion it carries a low intrinsic risk of hypoglycemia. In practice it serves as the backbone of combination regimens alongside agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors including empagliflozin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 agonists, and insulin therapy. Its principal safety concern is lactic acidosis, a rare but serious complication associated with impaired drug clearance; for this reason dosing is guided by glomerular filtration rate and the drug is generally avoided in advanced renal failure and dialysis, where metformin-associated lactic acidosis and encephalopathy have been reported. Nitrosamine impurity findings in certain tablet formulations have also drawn regulatory attention.
At the molecular level, metformin is generally described as an inhibitor of mitochondrial electron transport chain complex I, which raises the cellular AMP-to-adenosine triphosphate ratio and activates AMP-activated protein kinase, including through the upstream kinase CaMKKβ. AMPK activation, mediated in part by the AMPKα1 subunit, restrains mTORC1 signaling and shifts cells toward catabolic metabolism, with additional AMPK-independent effects reported. These energy-sensing actions underlie broad interest in repurposing metformin beyond glycemic control: preclinical and computational studies examine it in cancers such as hepatocellular carcinoma, head and neck squamous cell carcinoma, and breast cancer, where Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/mTOR, JAK2/STAT3, and glycolytic pathways are implicated, and in neurodegeneration and cognitive impairment, inflammatory disease, chronic pain, age-related bone loss, and tissue repair. Reported downstream effects include modulation of autophagy and mitophagy, ferroptosis, reactive oxygen species and oxidative stress, NLRP3 inflammasome activity and proinflammatory cytokine release, apoptotic regulators such as Bcl-2 and caspase-3, and macrophage inflammatory polarization. These repurposing applications remain investigational rather than established indications.
Where the papers sit
54 papers from the last 6 months study metformin directly · updated from PubMed 16 Nov 2026
Study type 6 clinical trials · 8 observational · 7 human data · 30 preclinical · 3 unclassified
Themes 6 themes · 1 new direction
-
Metabolic Inflammation and Tissue Protection
Metformin is being positioned as a protective adjunct across insulin resistance, gestational diabetes, PCOS, obesity, and related tissue injury. Ferroptosis recurs in podocytes, granulosa cells, and trophoblasts, with SLC7A11-GPX4, ATF2, PI3K/Akt/Nrf2, and fatty-acid metabolism among the proposed mechanisms. Probiotics, vitamin D3, botanical agents, taurine, and bariatric surgery are being explored as complementary strategies. Evidence remains mixed across preclinical, randomized, pharmacokinetic, and safety settings.
20 papers · 37%
-
Type 2 Diabetes Outcomes
Type 2 diabetes research is moving toward individualized treatment response and broader disease management. Genetic variation, body weight, gut-microbial degradation by AdhE, and nutrition may explain why metformin efficacy differs between patients. Combination therapy with HTD1801 and associations with bone, hearing, mood, vascular, and readmission outcomes extend evaluation beyond glucose control. Most complication findings remain observational or early translational evidence.
10 papers · 18.5%
-
Cancer Metabolism and Combination Therapy
Cancer treatment is shifting toward combining metformin with cytotoxic, photodynamic, or immune-based approaches. Doxorubicin delivery systems and metformin sensitization recur in breast and liver cancer, with EMT and microRNA regulation implicated in response. GLUT1/SGLT1 balance, lysosomal deacidification, mTORC1 inhibition, hypoxia, and tunnelling nanotubes identify metabolic and microenvironmental vulnerabilities. Clinical breast cancer data are beginning to test whether these preclinical mechanisms improve outcomes.
7 papers · 13%
-
Diabetes Complications and Cancer Risk
Long-term metformin exposure is being evaluated for effects beyond glycemic control, especially diabetic nephropathy and hepatocellular carcinoma risk. Cohort and Mendelian-randomization analyses suggest dose- or duration-related protection, but observational associations do not establish causality. Prediabetes interventions also examine multimorbidity, while real-world data address treatment-related hyperglycemia during alpelisib therapy. Molecular modeling and nanoparticle formulations remain exploratory routes for validating or extending these clinical signals.
6 papers · 11.1%
-
Oxidative Stress and Tissue Protection
Oxidative stress and hyperglycemia are recurring targets for metformin-based tissue protection. Metformin is linked to reduced neuroinflammation and oxidative injury in models of maternal stress, Parkinsonism, and diabetic complications. Nanoceria, glucose oxidase, microneedles, and empagliflozin combinations point toward localized or adjunctive delivery. Evidence remains largely preclinical, with tissue repair and functional recovery still requiring confirmation.
4 papers · 7.4%
-
Others — Metabolic Therapy Across Diseases
Therapeutic development spans metformin analogues, enzyme inhibition, targeted delivery, photodynamic therapy, and immune checkpoint combinations. Head and neck cancer work is testing metformin with pembrolizumab or methylene blue, while computational studies seek pathway-directed analogues. Separate programs investigate diosgenin against pulmonary fibrosis and intestinally targeted metformin release. The disease areas and mechanisms are too diverse to support one dominant biological direction.
7 papers · 13%
Metformin is a gut-microbial substrate whose degradation determines its therapeutic response
The type 2 diabetes gut-microbe study 42810351Sep moves beyond treating metformin solely as an active drug whose response varies among patients: it found that AdhE produced by low-response Eubacterium converts metformin into pharmacologically inactive products, reducing intestinal and systemic exposure. Eliminating the AdhE-producing bacteria or inhibiting AdhE with daidzein restored metformin exposure and glycemic control in mice. Metformin therefore becomes the target of a microbiome-directed intervention, with microbial enzyme depletion or inhibition proposed as a way to rescue therapy.
Papers
The 54 papers from the last 6 months that study metformin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Metabolic Inflammation and Tissue Protection (20)
- Anti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol. PloS one · 12 Nov 2026 PMID 43019369
- Effects of Lactobacillus crispatus-Containing Probiotics and Metformin on Insulin Resistance, Inflammation, and Gut Microbiome in Polycystic Ovary Syndrome: Protocol for an Open-Label Randomized Controlled Trial. JMIR research protocols · 5 Nov 2026 PMID 42987300
- Long-Term Post-Mitotic Culture of Human Fibroblasts Recapitulates and Accelerates Features of In Vivo Aging and Enables Dynamic Testing of Anti-Aging Compounds. Aging cell · 1 Nov 2026 PMID 42967595
- Exploring the Therapeutic Potential of Metformin and Vitamin D3 Combination in the Management of Diabetes Mellitus. Endocrinology, diabetes & metabolism · 1 Nov 2026 PMID 42967578
- Sustained release of metformin through an injectable hydrogel for synergistic macrophage reprogramming and ROS scavenging in the analgesic treatment of osteoarthritis. Drug delivery · 29 Oct 2026 PMID 42952350
- Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density. Journal of molecular histology · 5 Oct 2026 PMID 42831968
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single-Center, Single-Arm, Phase I Study in China. Clinical pharmacology in drug development · 30 Sept 2026 PMID 42811461
- Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
- NR4A1-Driven Granulosa Cell Ferroptosis Contributes to Obesity-Related Ovarian Dysfunction and Metformin-Mediated Ovarian Protection. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 25 Sept 2026 PMID 42789330
- Metformin Inhibits Trophoblast Ferroptosis by Suppressing ATF2 and Activating the PI3K/Akt/Nrf2 Pathway to Improve Gestational Diabetes Mellitus. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 23 Sept 2026 PMID 42775709
- Neuroprotective impact of nicotinamide riboside and metformin on the hippocampus of male rats with diet-induced obesity. Metabolic brain disease · 11 Sept 2026 PMID 42726148
- Additive effects of metformin on glucose homeostasis after metabolic-bariatric surgery in nonobese insulin-deficient diabetic rats. American journal of physiology. Endocrinology and metabolism · 3 Sept 2026 PMID 42691476
- The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial agents and chemotherapy · 6 Aug 2026 PMID 42560062
- Metformin protects podocytes by inhibiting the MAPK14-SLC7A11-GPX4 axis and dysregulation of fatty acid metabolism. Diabetologia · 3 Aug 2026 PMID 42547585
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- Multi-omics Mendelian randomization and experimental validation identify PRKAB1 as a regulator of phosphatidylcholine metabolism in IBD. Naunyn-Schmiedeberg's archives of pharmacology · 13 Jul 2026 PMID 42443636
- Combined metformin and Taurine attenuate age-related bone loss. Molecular biology reports · 27 Jun 2026 PMID 42364025
- An MFO@BCZT- and metformin-integrated biomimetic hydrogel for magnetoelectric stimulation-induced neurogenesis and neuroprotection, synergistically promoting brain tissue repair. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300462
- A case of metformin-associated encephalopathy in a patient undergoing maintenance hemodialysis. CEN case reports · 14 Jun 2026 PMID 42289604
- An antiswelling biodegradable hydrogel reshapes electro-microenvironment to drive endogenous neuroregeneration after brain defect. Science advances · 29 May 2026 PMID 42213827
Type 2 Diabetes Outcomes (10)
- Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats. BMC oral health · 4 Nov 2026 PMID 42983448
- Metformin-supportive nutrition: When gut microbes eat drugs. Cell metabolism · 3 Nov 2026 PMID 42976769
- Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes. Cell metabolism · 29 Sept 2026 PMID 42810351
- Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing-Impaired Patients With Type 2 Diabetes. Pharmacology research & perspectives · 10 Sept 2026 PMID 42717744
- Metformin alleviates type 2 diabetes-related depressive-like behaviors via AKAP150 signaling in NAc D1 medium spiny neurons. Pharmacological research · 9 Sept 2026 PMID 42716236
- Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts. Diabetes, obesity & metabolism · 2 Sept 2026 PMID 42681821
- The Association Between Type 2 Diabetes and Bone Microarchitecture Assessed by HR-pQCT. Calcified tissue international · 14 Aug 2026 PMID 42595905
- Association of glucose-lowering agents with readmission risk in patients with rheumatoid arthritis and comorbid type 2 diabetes mellitus. Pharmacological research · 6 Aug 2026 PMID 42562084
- Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets. Annals of human genetics · 23 Jul 2026 PMID 42487515
- HTD1801 in Combination with Metformin for Type 2 Diabetes. NEJM evidence · 7 Jun 2026 PMID 42251702
Cancer Metabolism and Combination Therapy (7)
- Metformin sensitizes HepG2 liver cancer cells to doxorubicin through epithelial to mesenchymal transition and microRNA regulation. Medical oncology (Northwood, London, England) · 10 Nov 2026 PMID 43007581
- Biomimetic platelet membrane-camouflaged nanomicelles for synergistic hypoxia alleviation and immune activation to potentiate immunotherapy in TNBC. International journal of pharmaceutics · 19 Sept 2026 PMID 42763079
- GLUT1/SGLT1 balance associates with high-glucose buffering of metformin-induced lysosomal deacidification and mTORC1 inhibition in colorectal cancer. European journal of pharmacology · 21 Aug 2026 PMID 42628623
- Dual delivery of metformin and doxorubicin via the gum acacia-gelatin nanohydrogel disrupts tunnelling nanotube-mediated breast cancer progression. Biomaterials science · 17 Aug 2026 PMID 42605874
- Impact of Metformin Use on Clinical and Pathological Outcomes in Breast Cancer Patients With Type 2 Diabetes. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42528302
- Repurposing triamterene as chloride intracellular channel 1 inhibitor via ligand-based approach for glioblastoma. Molecular therapy : the journal of the American Society of Gene Therapy · 19 Jul 2026 PMID 42471757
- A simple oral STZ/alloxan-induced diabetic zebrafish model for chronic wound healing and therapeutic assessment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 20 May 2026 PMID 42161227
Diabetes Complications and Cancer Risk (6)
- Dose-Dependent Association of Long-Term Metformin Use and Diabetic Nephropathy Risk in Patients with Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Taiwan. Clinical drug investigation · 12 Sept 2026 PMID 42730863
- Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study. Liver international : official journal of the International Association for the Study of the Liver · 25 Jul 2026 PMID 42499017
- Network toxicology-driven repurposing of metformin for hepatocellular carcinoma: insights from molecular docking and dynamics simulations. Journal of molecular modeling · 18 Jul 2026 PMID 42470472
- Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA · 15 Jun 2026 PMID 42295772
- Development of metformin-encapsulated poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles. Molecular biology reports · 28 May 2026 PMID 42207379
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
Oxidative Stress and Tissue Protection (4)
- Redox-Active Nanoceria Integrated with Glucose Oxidase for Glucose-Triggered Metformin Release: Promising Nanocarrier for Managing Oxidative Stress and Hyperglycemia in Diabetes Pathophysiology. ACS applied bio materials · 20 Oct 2026 PMID 42899421
- Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
- Metformin Partially Lessens Autism-Related Behaviors in Mice Subjected to Maternal Separation Stress by Combating Hippocampal Neuroinflammation and Oxidative Stress Imbalance. Journal of biochemical and molecular toxicology · 1 Jun 2026 PMID 42224401
- Multifunctional spatiotemporally programmed microneedle patches for the reconstruction of antibacterial and immunoregenerative homeostasis in periodontitis therapy. Acta biomaterialia · 24 May 2026 PMID 42178084
Others — Metabolic Therapy Across Diseases (7)
- Yin-Huang-Qing-Fei-Capsule derived diosgenin and its optimized nanoconjugate target STAT3 against pulmonary fibrosis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 24 Jul 2026 PMID 42497519
- A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
- Investigation of metformin analogues in targeting signaling molecules of head and neck cancer pathways by computational approaches. Scientific reports · 22 Jun 2026 PMID 42331865
- Metformin enhances methylene blue-mediated photodynamic therapy in oral squamous cell carcinoma. Journal of the Egyptian National Cancer Institute · 21 Jun 2026 PMID 42324424
- Exploring the competitive inhibition mechanism of α-glucosidase by metformin. Bioorganic chemistry · 18 Jun 2026 PMID 42314600
- An Integrated Pharmacological Evaluation and GC-MS/MS-Guided Metabolite Profiling of Diospyros sylvatica Roxb. Leaves Revealing Analgesic, Antioxidant, and Antidiabetic Activities. Chemistry & biodiversity · 31 May 2026 PMID 42218796
- Developing an enzyme-assembled phytoglycogen-based carrier for intestinal-targeted delivery of metformin. International journal of biological macromolecules · 25 May 2026 PMID 42184840
By study type
Clinical trials (6)
- Effects of Lactobacillus crispatus-Containing Probiotics and Metformin on Insulin Resistance, Inflammation, and Gut Microbiome in Polycystic Ovary Syndrome: Protocol for an Open-Label Randomized Controlled Trial. JMIR research protocols · 5 Nov 2026 PMID 42987300
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single-Center, Single-Arm, Phase I Study in China. Clinical pharmacology in drug development · 30 Sept 2026 PMID 42811461
- The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial agents and chemotherapy · 6 Aug 2026 PMID 42560062
- A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
- Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA · 15 Jun 2026 PMID 42295772
- HTD1801 in Combination with Metformin for Type 2 Diabetes. NEJM evidence · 7 Jun 2026 PMID 42251702
Observational studies and case reports (8)
- Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
- Dose-Dependent Association of Long-Term Metformin Use and Diabetic Nephropathy Risk in Patients with Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Taiwan. Clinical drug investigation · 12 Sept 2026 PMID 42730863
- Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing-Impaired Patients With Type 2 Diabetes. Pharmacology research & perspectives · 10 Sept 2026 PMID 42717744
- Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts. Diabetes, obesity & metabolism · 2 Sept 2026 PMID 42681821
- The Association Between Type 2 Diabetes and Bone Microarchitecture Assessed by HR-pQCT. Calcified tissue international · 14 Aug 2026 PMID 42595905
- Impact of Metformin Use on Clinical and Pathological Outcomes in Breast Cancer Patients With Type 2 Diabetes. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42528302
- Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets. Annals of human genetics · 23 Jul 2026 PMID 42487515
- A case of metformin-associated encephalopathy in a patient undergoing maintenance hemodialysis. CEN case reports · 14 Jun 2026 PMID 42289604
Human data, design not indexed (7)
- Long-Term Post-Mitotic Culture of Human Fibroblasts Recapitulates and Accelerates Features of In Vivo Aging and Enables Dynamic Testing of Anti-Aging Compounds. Aging cell · 1 Nov 2026 PMID 42967595
- Association of glucose-lowering agents with readmission risk in patients with rheumatoid arthritis and comorbid type 2 diabetes mellitus. Pharmacological research · 6 Aug 2026 PMID 42562084
- Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study. Liver international : official journal of the International Association for the Study of the Liver · 25 Jul 2026 PMID 42499017
- Network toxicology-driven repurposing of metformin for hepatocellular carcinoma: insights from molecular docking and dynamics simulations. Journal of molecular modeling · 18 Jul 2026 PMID 42470472
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- Investigation of metformin analogues in targeting signaling molecules of head and neck cancer pathways by computational approaches. Scientific reports · 22 Jun 2026 PMID 42331865
- Exploring the competitive inhibition mechanism of α-glucosidase by metformin. Bioorganic chemistry · 18 Jun 2026 PMID 42314600
Preclinical: animal, cell and lab studies (30)
- Anti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol. PloS one · 12 Nov 2026 PMID 43019369
- Metformin sensitizes HepG2 liver cancer cells to doxorubicin through epithelial to mesenchymal transition and microRNA regulation. Medical oncology (Northwood, London, England) · 10 Nov 2026 PMID 43007581
- Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats. BMC oral health · 4 Nov 2026 PMID 42983448
- Metformin-supportive nutrition: When gut microbes eat drugs. Cell metabolism · 3 Nov 2026 PMID 42976769
- Exploring the Therapeutic Potential of Metformin and Vitamin D3 Combination in the Management of Diabetes Mellitus. Endocrinology, diabetes & metabolism · 1 Nov 2026 PMID 42967578
- Sustained release of metformin through an injectable hydrogel for synergistic macrophage reprogramming and ROS scavenging in the analgesic treatment of osteoarthritis. Drug delivery · 29 Oct 2026 PMID 42952350
- Redox-Active Nanoceria Integrated with Glucose Oxidase for Glucose-Triggered Metformin Release: Promising Nanocarrier for Managing Oxidative Stress and Hyperglycemia in Diabetes Pathophysiology. ACS applied bio materials · 20 Oct 2026 PMID 42899421
- Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density. Journal of molecular histology · 5 Oct 2026 PMID 42831968
- Microbial aldehyde-alcohol dehydrogenase degrades metformin to limit therapeutic response in type 2 diabetes. Cell metabolism · 29 Sept 2026 PMID 42810351
- NR4A1-Driven Granulosa Cell Ferroptosis Contributes to Obesity-Related Ovarian Dysfunction and Metformin-Mediated Ovarian Protection. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 25 Sept 2026 PMID 42789330
- Metformin Inhibits Trophoblast Ferroptosis by Suppressing ATF2 and Activating the PI3K/Akt/Nrf2 Pathway to Improve Gestational Diabetes Mellitus. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 23 Sept 2026 PMID 42775709
- Biomimetic platelet membrane-camouflaged nanomicelles for synergistic hypoxia alleviation and immune activation to potentiate immunotherapy in TNBC. International journal of pharmaceutics · 19 Sept 2026 PMID 42763079
- Neuroprotective impact of nicotinamide riboside and metformin on the hippocampus of male rats with diet-induced obesity. Metabolic brain disease · 11 Sept 2026 PMID 42726148
- Metformin alleviates type 2 diabetes-related depressive-like behaviors via AKAP150 signaling in NAc D1 medium spiny neurons. Pharmacological research · 9 Sept 2026 PMID 42716236
- Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
- Additive effects of metformin on glucose homeostasis after metabolic-bariatric surgery in nonobese insulin-deficient diabetic rats. American journal of physiology. Endocrinology and metabolism · 3 Sept 2026 PMID 42691476
- GLUT1/SGLT1 balance associates with high-glucose buffering of metformin-induced lysosomal deacidification and mTORC1 inhibition in colorectal cancer. European journal of pharmacology · 21 Aug 2026 PMID 42628623
- Dual delivery of metformin and doxorubicin via the gum acacia-gelatin nanohydrogel disrupts tunnelling nanotube-mediated breast cancer progression. Biomaterials science · 17 Aug 2026 PMID 42605874
- Yin-Huang-Qing-Fei-Capsule derived diosgenin and its optimized nanoconjugate target STAT3 against pulmonary fibrosis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 24 Jul 2026 PMID 42497519
- Repurposing triamterene as chloride intracellular channel 1 inhibitor via ligand-based approach for glioblastoma. Molecular therapy : the journal of the American Society of Gene Therapy · 19 Jul 2026 PMID 42471757
- Combined metformin and Taurine attenuate age-related bone loss. Molecular biology reports · 27 Jun 2026 PMID 42364025
- Metformin enhances methylene blue-mediated photodynamic therapy in oral squamous cell carcinoma. Journal of the Egyptian National Cancer Institute · 21 Jun 2026 PMID 42324424
- An MFO@BCZT- and metformin-integrated biomimetic hydrogel for magnetoelectric stimulation-induced neurogenesis and neuroprotection, synergistically promoting brain tissue repair. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300462
- Metformin Partially Lessens Autism-Related Behaviors in Mice Subjected to Maternal Separation Stress by Combating Hippocampal Neuroinflammation and Oxidative Stress Imbalance. Journal of biochemical and molecular toxicology · 1 Jun 2026 PMID 42224401
- An Integrated Pharmacological Evaluation and GC-MS/MS-Guided Metabolite Profiling of Diospyros sylvatica Roxb. Leaves Revealing Analgesic, Antioxidant, and Antidiabetic Activities. Chemistry & biodiversity · 31 May 2026 PMID 42218796
- An antiswelling biodegradable hydrogel reshapes electro-microenvironment to drive endogenous neuroregeneration after brain defect. Science advances · 29 May 2026 PMID 42213827
- Development of metformin-encapsulated poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles. Molecular biology reports · 28 May 2026 PMID 42207379
- Developing an enzyme-assembled phytoglycogen-based carrier for intestinal-targeted delivery of metformin. International journal of biological macromolecules · 25 May 2026 PMID 42184840
- Multifunctional spatiotemporally programmed microneedle patches for the reconstruction of antibacterial and immunoregenerative homeostasis in periodontitis therapy. Acta biomaterialia · 24 May 2026 PMID 42178084
- A simple oral STZ/alloxan-induced diabetic zebrafish model for chronic wound healing and therapeutic assessment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 20 May 2026 PMID 42161227
Unclassified: not yet indexed with MeSH (3)
- Metformin protects podocytes by inhibiting the MAPK14-SLC7A11-GPX4 axis and dysregulation of fatty acid metabolism. Diabetologia · 3 Aug 2026 PMID 42547585
- Multi-omics Mendelian randomization and experimental validation identify PRKAB1 as a regulator of phosphatidylcholine metabolism in IBD. Naunyn-Schmiedeberg's archives of pharmacology · 13 Jul 2026 PMID 42443636
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
Written from 54 PubMed abstracts, each one listed by PMID above. Published: 2026-06-25. Last written: 2026-09-13 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.